8.00
+0.19(+2.43%)
Currency In USD
| Previous Close | 7.81 |
| Open | 7.7 |
| Day High | 8.01 |
| Day Low | 7.46 |
| 52-Week High | 8.01 |
| 52-Week Low | 1.34 |
| Volume | 507,971 |
| Average Volume | 1.07M |
| Market Cap | 268.59M |
| PE | -10.39 |
| EPS | -0.77 |
| Moving Average 50 Days | 5.72 |
| Moving Average 200 Days | 3.39 |
| Change | 0.19 |
If you invested $1000 in Immix Biopharma, Inc. (IMMX) since IPO date, it would be worth $2,179.84 as of February 21, 2026 at a share price of $8. Whereas If you bought $1000 worth of Immix Biopharma, Inc. (IMMX) shares 3 years ago, it would be worth $3,864.73 as of February 21, 2026 at a share price of $8.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201
GlobeNewswire Inc.
Jan 28, 2026 1:45 PM GMT
– Breakthrough Therapy Designation granted to NXC-201 based on positive NEXICART-2 Phase 2 interim clinical results, presented at the American Society of Hematology (ASH) 2025 annual meeting – – Final data expected this year followed by planned BLA s
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Dec 09, 2025 10:45 PM GMT
– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in relapsed/refract
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Dec 07, 2025 11:20 PM GMT
LOS ANGELES, CA, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten registered offering of 1